Breaking News Instant updates and real-time market news.
2019-02-13 16:23:10
NGVT
Ingevity
$96.93
-1.52 (-1.54%)
16:23
02/13/19
02/13
16:23
02/13/19
16:23
Ingevity reports Q4 EPS $1.07, consensus 77c
Reports Q4 revenue $278.6M, consensus $265.59M. Q4 Adjusted EBITDA of $73.3M vs. $52.6M last year. Q4 adjusted EBITDA margin of 26.3% improved 340bps from last year.
14
Feb
NGVTIngevity
$96.93
-1.52 (-1.54%)
10/02/18
BREN
10/02/18 DOWNGRADETarget $110 BREN Hold
Ingevity downgraded to Hold from Buy at Berenberg
Berenberg analyst Paretosh Misra downgraded Ingevity to Hold and lowered his price target for the shares to $110 from $115. The spot price weakness in fatty acids and gum rosin commodities may hurt pricing in parts of the Performance Chemicals business, Misra tells investors in a research note. With the stock up 47% year-to-date, the analyst now sees a more balanced risk/reward.
10/19/18
JEFF
10/19/18 NO CHANGETarget $115 JEFF Buy
Ingevity valuation reasonable after 10% pullback, says Jefferies
Jefferies analyst Daniel Rizzo sees a "reasonable" valuation on Ingevity with the stock down 10% in the past month. The analyst attributes the selloff to concerns of slower auto production and a decline in TOR spot prices in China. However, U.S. TOR prices remain stable, and any auto deceleration "should be masked by the step-change in worldwide fuel vapor emission standards," Rizzo tells investors in a research note titled "Secular Growth Should Shine In A Choppy Macro Environment." The analyst keeps a Buy rating on Ingevity with a $115 price target.
12/10/18
STFL
12/10/18 INITIATIONTarget $84 STFL Hold
Ingevity initiated with a Hold at Stifel
Stifel analyst Vincent Anderson initiated Ingevity with a Hold rating and a price target of $84. The analyst notes that the stock offers a "strong, visible growth profile from dominant market share position", but also believes that investors may be underestimating its longer-term risks. Anderson is also neutral on the company's recently announced acquisition given that the deal's "price, lack of synergies, and near-term market risk offset good long-term strategic value."
12/13/18
LOOP
12/13/18 NO CHANGETarget $95 LOOP Hold
Ingevity sell-off on Capa deal 'too punitive', says Loop Capital
Loop Capital analyst Chris Kapsch writes that the sell-off in Ingevity stock price after its $675M acquisition of Capa business from Perstorp AB is "too punitive", saying the additional due diligence that he did on the deal supports his view of 10% earnings accretion next year. The analyst keeps his Hold rating and $95 price target on Ingevity longer term.